Literature DB >> 9680247

The role of subtypes of the opioid receptor in the anxiolytic action of chlordiazepoxide.

A Agmo1, C Belzung.   

Abstract

Previous studies have shown that the opiate antagonist naloxone blocks the anxiolytic-like effects of benzodiazepines in several models of anxiety, including the elevated plus-maze. Although naloxone preferentially binds to the mu opioid receptor, its selectivity is rather low. The opioid receptor subtype important for anxiolytic-like actions of benzodiazepines in the plus-maze remains, therefore, unknown. In the present experiments, the ability of antagonists selective for subtypes of the opioid receptor to block the anxiolytic-like effects of chlordiazepoxide in the elevated plus-maze was evaluated in Swiss mice. Chlordiazepoxide, 5 mg/kg, increased the proportion as well as the number of open arms entries without modifying closed arms entries. Lower doses of the benzodiazepine were ineffective. The mu receptor antagonist beta-funaltrexamine, 10 and 20 mg/kg, the delta antagonist naltrindole, 10 mg/kg, and the kappa antagonist nor-binaltorphimine, 2.5 and 5 mg/kg, were then combined with chlordiazepoxide, 5 mg/kg. beta-funaltrexamine, 10 mg/kg, reduced the effects of the benzodiazepine while the dose of 20 mg/kg completely blocked the effects. Nor-binaltorphimine was ineffective at a dose of 2.5 mg/kg, but completely inhibited the actions of chlordiazepoxide when the dose was 5 mg/kg. Naltrindole was ineffective. None of the antagonists affected plus-maze behavior when administered alone. It was concluded that the mu and kappa receptors are important for the anxiolytic-like actions of chlordiazepoxide in the elevated plus maze.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9680247     DOI: 10.1016/s0028-3908(98)00003-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Interleukin-1beta-induced brain injury and neurobehavioral dysfunctions in juvenile rats can be attenuated by alpha-phenyl-n-tert-butyl-nitrone.

Authors:  L W Fan; L T Tien; B Zheng; Y Pang; P G Rhodes; Z Cai
Journal:  Neuroscience       Date:  2010-03-24       Impact factor: 3.590

2.  Neonatal lipopolysaccharide exposure induces long-lasting learning impairment, less anxiety-like response and hippocampal injury in adult rats.

Authors:  K-C Wang; L-W Fan; A Kaizaki; Y Pang; Z Cai; L-T Tien
Journal:  Neuroscience       Date:  2013-01-05       Impact factor: 3.590

3.  Atypical anxiolytic-like response to naloxone in benzodiazepine-resistant 129S2/SvHsd mice: role of opioid receptor subtypes.

Authors:  R J Rodgers; R Augar; N Berryman; C J Hansom; M L O'Mahony; R M Palmer; A Stevens; A J Tallett
Journal:  Psychopharmacology (Berl)       Date:  2006-06-27       Impact factor: 4.530

4.  Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 2: effects of substitutions on pharmacological activity.

Authors:  Wei-Jie Fang; Marco A Bennett; Thomas F Murray; Jane V Aldrich
Journal:  Biopolymers       Date:  2011       Impact factor: 2.505

5.  Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 1: effects of cleavage conditions and N-terminal functionality.

Authors:  Wei-Jie Fang; Marco A Bennett; Jane V Aldrich
Journal:  Biopolymers       Date:  2011       Impact factor: 2.505

6.  Microinjection of naltrexone into the central, but not the basolateral, amygdala blocks the anxiolytic effects of diazepam in the plus maze.

Authors:  Paul R Burghardt; Marlene A Wilson
Journal:  Neuropsychopharmacology       Date:  2006-06       Impact factor: 7.853

7.  Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats.

Authors:  Akiyoshi Saitoh; Yuji Yoshikawa; Kenji Onodera; Junzo Kamei
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

8.  Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats.

Authors:  Shuying Lin; Lir-Wan Fan; Philip G Rhodes; Zhengwei Cai
Journal:  Exp Neurol       Date:  2009-03-28       Impact factor: 5.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.